FindTrial
Sign In

Prospective study on the evaluation of residual viable tumors after immune targeted conversion therapy for liver cancer using contrast-enhanced ultrasound

Prospective study on the evaluation of residual viable tumors after immune targeted conversion therapy for liver cancer using contrast-enhanced ultrasound

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600127949
Enrollment
Unknown
Registered
2026-07-10
Start date
2026-07-10
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver carcinoma

Interventions

Resiudual viable tumor:None
No resiudual viable tumor:None

Sponsors

The First Medical Center, Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Pathological or clinical diagnosis of HCC; 2. HCC patients who have undergone immune-targeted conversion therapy; 3. Underwent contrast-enhanced ultrasound (CEUS) examination after immune-targeted conversion therapy; 4. Received surgical resection following CEUS examination.

Exclusion criteria

Exclusion criteria: 1. Incomplete clinical or pathological information; 2. Interruption or alteration of the immune-targeted conversion therapy regimen; 3. Poor quality of contrast-enhanced ultrasound (CEUS) images; 4. An interval of more than 2 weeks between surgery and CEUS examination.

Design outcomes

Primary

MeasureTime frame
Resiudual viable tumor;—

Countries

China

Contacts

Public ContactLianhua Zhu

The First Medical Center, Chinese PLA General Hospital

zhulianhua27@163.com+86 158 1088 5024

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026